Loyola University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Chicago IL United States (1870)

Organization Overview

First Clinical Trial
1989
NCT00929591
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Bital Savir-Baruch | Cardinal Bernardin Cancer Center, Loyola University | Department Anesthesiology Loyola University Medical Center | Elizabeth Henry | Loyola Medical Center | Loyola Univeristy Medical Center | Loyola Univerity Medical Center | Loyola University | Loyola University Cardinal Bernadin Cancer Center | Loyola University Cardinal Bernardin Cancer Center | Loyola University Chicago | Loyola University Chicago Health Sciences Division | Loyola University Health System | Loyola University Medical Center | Loyola University Medical Center, Department of Surgery | Loyola University Medical Center (LUMC) | Loyola University Medical Center, Maywood, IL | Loyola Univ Med Cntr- | Loyola Univ Med Cntr - Cardinal Bernardin Cancer Cntr | Loyola Univ Med Cntr - Dept of Urology & Obstetrics/Gynecology | Marsha Ma | Patrick Stiff | Steven Edelstein

Active Ingredients

Drugs in Phase 4 Trials (36)

aprepitant (Emend) (1 trial)

azathioprine (imuran) (1 trial)

belladonna (1 trial)

bromocriptine (parlodel) (1 trial)

cabergoline (dostinex) (1 trial)

celecoxib (celebrex) (1 trial)

enoxaparin (lovenox) (1 trial)

escitalopram (lexapro) (1 trial)

estrogen (1 trial)

Fluciclovine (Axumin) (1 trial)

gadoteric acid (Dotarem) (1 trial)

hydroxyurea (hydrea) (1 trial)

insulin human (humulin) (1 trial)

ivabradine (corlanor) (1 trial)

ketamine (ketalar) (2 trials)

levetiracetam (keppra) (1 trial)

melatonin (1 trial)

mirabegron (myrbetriq) (1 trial)

misoprostol (cytotec) (1 trial)

naloxone (narcan) (1 trial)

ondansetron (zofran) (1 trial)

oxytocin (syntocinon) (1 trial)

papaver somniferum resin (1 trial)

phenazopyridine (gantanol) (1 trial)

quetiapine (seroquel) (1 trial)

rocuronium (zemuron) (1 trial)

ropivacaine (naropin) (2 trials)

rosuvastatin (crestor) (1 trial)

sirolimus (rapamune) (1 trial)

sodium chloride (3 trials)

solifenacin (vesicare) (3 trials)

sugammadex (bridion) (1 trial)

tacrolimus (prograf) (4 trials)

timolol (blocadren) (1 trial)

urea (3 trials)

vortioxetine (trintellix) (1 trial)

Drugs in Phase 3 Trials (35)

aldesleukin (proleukin) (3 trials)

alefacept (Amevive) (1 trial)

atorvastatin (lipitor) (1 trial)

autologous bone marrow (2 trials)

bleomycin (blenoxane) (3 trials)

carboplatin (paraplatin) (4 trials)

carlecortemcel-l (2 trials)

carmustine (bicnu) (3 trials)

cisplatin (platinol) (1 trial)

cyclophosphamide (cytoxan) (14 trials)

dacarbazine (dtic-dome) (1 trial)

doxorubicin (Doxil) (6 trials)

epirubicin (ellence) (1 trial)

epoetin (Epogen) (1 trial)

etoposide (vepesid) (7 trials)

fentanyl (Innovar) (2 trials)

fluorouracil (efudex) (2 trials)

goserelin (zoladex) (1 trial)

ibandronate (boniva) (1 trial)

magnesium sulfate (Tis-U-Sol) (1 trial)

medroxyprogesterone (provera) (1 trial)

methotrexate (1 trial)

mitoxantrone (novantrone) (2 trials)

paclitaxel (taxol) (5 trials)

peripheral blood hematopoietic cell (5 trials)

prednisone (meticorten) (3 trials)

rimabotulinumtoxinB (Myobloc) (2 trials)

rituximab (rituxan) (2 trials)

sargramostim (leukine) (3 trials)

stk1-ligand (1 trial)

tamoxifen (nolvadex) (2 trials)

trichloroethanoic acid (1 trial)

vinblastine (velban) (1 trial)

vincristine (oncovin) (3 trials)

zoledronic acid (zometa) (1 trial)

Drugs in Phase 2 Trials (60)

allogeneic hematopoietic stem cells (Hemacord) (1 trial)

autologous-allogeneic tandem hematopoietic stem cell (1 trial)

azacitidine (vidaza) (3 trials)

aztreonam (azactam) (1 trial)

bendamustine (treanda) (1 trial)

betamethasone (celestone) (1 trial)

bevacizumab (avastin) (1 trial)

bortezomib (velcade) (1 trial)

busulfan (myleran) (1 trial)

capecitabine (xeloda) (2 trials)

carfilzomib (kyprolis) (1 trial)

cefepime (maxipeme) (1 trial)

ciprofloxacin (cipro) (2 trials)

clindamycin (cleocin) (1 trial)

cytarabine (cytosar-u) (4 trials)

daptomycin (cubicin) (1 trial)

deferasirox (exjade) (1 trial)

deferoxamine (desferal) (1 trial)

defibrotide (defitelio) (1 trial)

dendritic cells (1 trial)

denileukin diftitox (ontak) (2 trials)

docetaxel (taxotere) (1 trial)

fludarabine (fludara) (2 trials)

gallium nitrate (ganite) (1 trial)

gemtuzumab ozogamicin (mylotarg) (1 trial)

human fibrin (1 trial)

idarubicin (idamycin) (1 trial)

imatinib (gleevec) (1 trial)

immune globulin (human) (1 trial)

infliximab (remicade) (1 trial)

interferon alpha-2b (Intron-A) (2 trials)

lenalidomide (revlimid) (1 trial)

leucovorin (1 trial)

lidocaine (xylocaine) (1 trial)

linezolid (zyvox) (1 trial)

melphalan (alkeran) (3 trials)

meropenem (merrem) (1 trial)

methadone (methadose) (1 trial)

metronidazole (flagyl) (1 trial)

moxifloxacin (avelox) (1 trial)

mycophenolate (myfortic) (1 trial)

naltrexone (revia) (3 trials)

nicord (1 trial)

pazopanib (votrient) (1 trial)

piperacillin (pipracil) (1 trial)

prilocaine (citanest) (1 trial)

rice allergenic extract (1 trial)

saracatinib (1 trial)

sodium thiosulfate (1 trial)

sulfamethoxazole (gantanol) (2 trials)

tazobactam (Zosyn) (1 trial)

temozolomide (temodar) (1 trial)

temsirolimus (torisel) (1 trial)

thalidomide (Thalomid) (1 trial)

thrombin (bovine) (Thrombostat) (1 trial)

trimethoprim (2 trials)

valproic acid (depakene) (1 trial)

vancomycin (Vancocin) (1 trial)

vandetanib (caprelsa) (1 trial)

vitamin d3 (6 trials)

Drugs in Phase 1 Trials (5)

autologous bulk til 1383i tcr transduced t cells (1 trial)

autologous til 1383i tcr gene modified t cells (1 trial)

cd19-cd34 car transduced t cells (1 trial)

clofarabine (clolar) (1 trial)

herv-e tcr transduced cd8+/cd34+ t cells in hlaa* 11:01 positive patients (1 trial)

Drugs in Other Trials (10)

amoxicillin (1 trial)

bactrim (1 trial)

branched chain amino acids (1 trial)

bupivacaine (Exparel) (1 trial)

clavulanate (Augmentin) (1 trial)

conjugated equine estrogens (1 trial)

doxycycline (vibramycin) (1 trial)

epinephrine (levophed) (2 trials)

levobupivacaine (chirocaine) (2 trials)

mk-0752 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 4)

Anemia, Sickle Cell (Phase 4)

Atherosclerosis (Phase 4)

Bipolar Disorder (Phase 4)

Blood Loss, Surgical (Phase 4)

Brain Injuries (Phase 4)

Brain Injuries, Traumatic (Phase 4)

Breast Neoplasms (Phase 3)

Burns (Phase 4)

Calcinosis (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 4)

Carcinoma, Renal Cell (Phase 3)

Carcinoma, Squamous Cell (Phase 2)

Cerebral Hemorrhage (Phase 2)

Coronary Artery Disease (Phase 4)

Delayed Graft Function (Phase 4)

Delirium (Phase 4)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Depressive Disorder, Major (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Disease (Phase 4)

Endometrial Neoplasms (Phase 4)

Enuresis (Phase 3)

Fractures, Bone (Phase 4)

Headache (Phase 2)

Heart Failure (Phase 4)

Hemorrhage (Phase 4)

Hepatic Veno-Occlusive Disease (Phase 2)

Hip Fractures (Phase 4)

Hodgkin Disease (Phase 3)

Hypercalcemia (Phase 3)

Hypotension (Phase 3)

Ileus (Phase 4)

Infertility (Phase 3)

Inflammation (Phase 4)

Ischemia (Phase 4)

Kidney Neoplasms (Phase 3)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 3)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Lung Neoplasms (Phase 3)

Lymphangioleiomyomatosis (Phase 2)

Lymphoma (Phase 3)

Lymphoma, AIDS-Related (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Non-Hodgkin (Phase 3)

Melanoma (Phase 2)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 3)

Myocardial Ischemia (Phase 4)

Nausea (Phase 4)

Neoplasms (Phase 3)

Neoplasms, Plasma Cell (Phase 2)

Nocturia (Phase 4)

Osteomyelitis (Phase 2)

Ovarian Neoplasms (Phase 3)

Pain, Postoperative (Phase 2)

Pancreatic Neoplasms (Phase 2)

Pelvic Girdle Pain (Phase 2)

Peripheral Nervous System Diseases (Phase 2)

Plasmacytoma (Phase 2)

Polyneuropathies (Phase 2)

Postpartum Hemorrhage (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Preleukemia (Phase 3)

Psoriasis (Phase 3)

Renal Insufficiency (Phase 4)

Seizures (Phase 4)

Shock (Phase 4)

Shock, Cardiogenic (Phase 4)

Small Fiber Neuropathy (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stevens-Johnson Syndrome (Phase 2)

Syndrome (Phase 2)

Tachycardia (Phase 4)

Tachycardia, Ventricular (Phase 4)

Thromboembolism (Phase 4)

Urinary Bladder, Overactive (Phase 4)

Urinary Incontinence (Phase 3)

Urinary Incontinence, Urge (Phase 3)

Venous Thromboembolism (Phase 4)

Vitamin D Deficiency (Phase 2)

Vomiting (Phase 4)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 108
  • # of Trial APIs: 146